Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Rasmussen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Physical Chemistry Chemical Physics : PCCP|July 29, 2011
A cold and slow molecular beamHsin-I Lu, Julia Rasmussen, Matthew J Wright, et al.
Urologic Oncology|January 28, 2017
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancerSundhar Ramalingam, Michael S Humeniuk, Rachel Hu, et al.
Urologic Oncology|September 17, 2019
Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancerDaniel J George, Susan Halabi, Patrick Healy, et al.
European Urology Oncology|February 18, 2020
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM TrialRhonda L Bitting, Patrick Healy, Daniel J George, et al.
Human Molecular Genetics|August 13, 2003
Claudin 14 knockout mice, a model for autosomal recessive deafness DFNB29, are deaf due to cochlear hair cell degenerationTamar Ben-Yosef, Inna A Belyantseva, Thomas L Saunders, et al.
European Urology Oncology|July 6, 2024
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR TrialTian Zhang, Lauren Howard, Bridget F Koontz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2019
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY StudyAndrew J Armstrong, Susan Halabi, Jun Luo, et al.
Cancer|May 5, 2021
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancerDaniel J George, Susan Halabi, Elisabeth I Heath, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Physical Chemistry Chemical Physics : PCCP|July 29, 2011
A cold and slow molecular beamHsin-I Lu, Julia Rasmussen, Matthew J Wright, et al.
Urologic Oncology|January 28, 2017
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancerSundhar Ramalingam, Michael S Humeniuk, Rachel Hu, et al.
Urologic Oncology|September 17, 2019
Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancerDaniel J George, Susan Halabi, Patrick Healy, et al.
European Urology Oncology|February 18, 2020
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM TrialRhonda L Bitting, Patrick Healy, Daniel J George, et al.
Human Molecular Genetics|August 13, 2003
Claudin 14 knockout mice, a model for autosomal recessive deafness DFNB29, are deaf due to cochlear hair cell degenerationTamar Ben-Yosef, Inna A Belyantseva, Thomas L Saunders, et al.
European Urology Oncology|July 6, 2024
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR TrialTian Zhang, Lauren Howard, Bridget F Koontz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2019
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY StudyAndrew J Armstrong, Susan Halabi, Jun Luo, et al.
Cancer|May 5, 2021
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancerDaniel J George, Susan Halabi, Elisabeth I Heath, et al.
Pageof 1